Published in

Taylor & Francis, Expert Opinion on Therapeutic Targets, 12(17), p. 1497-1507

DOI: 10.1517/14728222.2013.838219

Links

Tools

Export citation

Search in Google Scholar

MicroRNAs and multiple sclerosis: from physiopathology toward therapy.

Journal article published in 2013 by Ameneh Zare-Shahabadi, Yves Renaudineau ORCID, Nima Rezaei
This paper is available in a repository.
This paper is available in a repository.

Full text: Download

Green circle
Preprint: archiving allowed
Green circle
Postprint: archiving allowed
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

INTRODUCTION: MicroRNAs (miRNAs) are an emerging group of small noncoding RNAs that regulate gene expression posttranscriptionally, by targeting messenger RNAs (mRNAs) for translational repression or degradation. They have roles in multiple facets of immunity, from regulation of cell development to activation and function in immune responses. Recent evidence underlines an involvement of miRNAs in the pathogenesis of autoimmune diseases as well as multiple sclerosis (MS). AREAS COVERED: In this review, the current knowledge of miRNA biogenesis, diverse roles of miRNAs in different cells that could be involved in the process of the disease, and their potential therapeutic applications are summarized. The authors searched MEDLINE and Science direct databases. EXPERT OPINION: The miRNAs in central nervous system lesions and peripheral blood are potential biomarkers for diagnostic and prognostic use. Also, miRNA mimics, small-molecule inhibitors of specific miRNAs, and antisense oligonucleotides could be therapeutic weapons that facilitate us to combat the disease.